{"nctId":"NCT04816669","briefTitle":"A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults","startDateStruct":{"date":"2021-04-01","type":"ACTUAL"},"conditions":["SARS-CoV-2 Infection","COVID-19"],"count":629,"armGroups":[{"label":"Lyophilized SDV","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b2"]},{"label":"Frozen liquid MDV (control for lyo SDV)","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b2"]},{"label":"Frozen-liquid with LNP size at the upper end of specification","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b2"]},{"label":"RTU","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b2"]},{"label":"Frozen liquid MDV (given as third dose following a primary series of lyophilized BNT162b2)","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b2"]}],"interventions":[{"name":"BNT162b2","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female participants 18 - 55 years of age, inclusive, at Visit 1, (Day 1).\n* Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.\n* Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. Note: Healthy participants with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrolment, can be included.\n* Capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in the protocol.\n* For Dose 3: Participants who received BOTH doses of the lyophilized formulation of BNT162b2 as part of the initial study.\n\nExclusion Criteria:\n\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\n* Known infection with HIV, HCV, or HBV.\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).\n* Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.\n* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\n* Women who are pregnant or breastfeeding.\n* Previous vaccination with any coronavirus vaccine.\n* Receipt of medications intended to prevent COVID-19.\n* Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for ≥14 days at a dose of ≥20 mg/day of prednisone or equivalent), eg, for cancer or an autoimmune disease, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.\n* Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.\n* Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation / Previous participation in other studies involving study intervention containing lipid nanoparticles (LNPs).\n* Previous participation in other studies involving study intervention containing lipid nanoparticles.\n* Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2","description":"GMTs of full-length S-binding IgG level for lyophilized formulation in SDVs and frozen-Liquid formulation in MDVs were reported in this outcome measure as geometric mean concentration (GMCs) in descriptive data section. GMC and 95 percent (%) confidence interval (CI) were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. Geometric mean ratio (GMR) was calculated as ratios of GMCs of BNT162b2 30 mcg lyophilized SDV and frozen-liquid MDV. GMR are reported in the statistical analysis section.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4796.8","spread":null},{"groupId":"OG001","value":"7031.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions Within 7 Days After Dose 1","description":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"3.6","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.1","spread":null},{"groupId":"OG001","value":"87.1","spread":null},{"groupId":"OG002","value":"85.7","spread":null},{"groupId":"OG003","value":"68.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions Within 7 Days After Dose 2","description":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"5.5","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.2","spread":null},{"groupId":"OG001","value":"80.3","spread":null},{"groupId":"OG002","value":"71.4","spread":null},{"groupId":"OG003","value":"62.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Dose 1","description":"Systemic events were reported using an electronic diary. Fever was defined as temperature \\>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 1 were reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3.2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":null},{"groupId":"OG001","value":"57.5","spread":null},{"groupId":"OG002","value":"54.3","spread":null},{"groupId":"OG003","value":"45.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"44.3","spread":null},{"groupId":"OG002","value":"37.1","spread":null},{"groupId":"OG003","value":"31.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"18.6","spread":null},{"groupId":"OG002","value":"8.6","spread":null},{"groupId":"OG003","value":"8.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"5.7","spread":null},{"groupId":"OG003","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":null},{"groupId":"OG001","value":"13.9","spread":null},{"groupId":"OG002","value":"5.7","spread":null},{"groupId":"OG003","value":"11.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"27.1","spread":null},{"groupId":"OG002","value":"11.4","spread":null},{"groupId":"OG003","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"15.4","spread":null},{"groupId":"OG002","value":"11.4","spread":null},{"groupId":"OG003","value":"17.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Dose 2","description":"Systemic events were reported using an electronic diary. Fever was defined as temperature \\>=38.0 degree C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 2 were reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"12.4","spread":null},{"groupId":"OG002","value":"2.9","spread":null},{"groupId":"OG003","value":"5.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"75.2","spread":null},{"groupId":"OG002","value":"48.6","spread":null},{"groupId":"OG003","value":"60.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null},{"groupId":"OG001","value":"61.7","spread":null},{"groupId":"OG002","value":"40.0","spread":null},{"groupId":"OG003","value":"40.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"22.9","spread":null},{"groupId":"OG003","value":"17.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"2.9","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"14.6","spread":null},{"groupId":"OG002","value":"8.6","spread":null},{"groupId":"OG003","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"43.1","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"37.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"32.1","spread":null},{"groupId":"OG002","value":"11.4","spread":null},{"groupId":"OG003","value":"28.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2","description":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 1","description":"GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 1","description":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2189.0","spread":null},{"groupId":"OG001","value":"3194.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2","description":"GMTs of full-length S-binding IgG level for frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs were reported in this outcome measure as GMCs in descriptive data section. GMC and 95 % CI were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ. GMR was calculated as ratios of GMCs of BNT162b2 30 mcg frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs. GMR are reported in the statistical analysis section.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7773.3","spread":null},{"groupId":"OG001","value":"6839.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMCs of Full-length S-binding IgG Levels at Baseline and 1 Month After Dose 2: Part 2","description":"GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7773.3","spread":null},{"groupId":"OG001","value":"6839.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 2","description":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3339.1","spread":null},{"groupId":"OG001","value":"2072.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Local Reactions Within 7 Days After Dose 3","description":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Systemic Events Within 7 Days After Dose 3","description":"Systemic events were reported using an electronic diary. Fever was defined as temperature \\>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 3 were reported.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With AEs and SAEs From Dose 3 to 1 Month After Dose 3","description":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 3","description":"GMFRs were defined as ratios of the geometric mean concentration of IgG from 1 month after Dose 3 to geometric mean concentration of IgG before Dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"GMCs of Full-Length S-Binding IgG Levels at Baseline, 1 Month After Dose 2, Before Dose 3, and 1 Month After Dose 3","description":"GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\\*LLOQ.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4612.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"874.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14006.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":279},"commonTop":["Injection site pain (PAIN)","Fatigue (FATIGUE)","Headache (HEADACHE)","Myalgia (MUSCLE PAIN)","Chills (CHILLS)"]}}}